TS-2021
Phase 1Biologic
TS-2021 is one of 51 biologic programs targeting Malignant Glioma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
199 competitors in Malignant Glioma
#DrugCompanyPhaseTrials
1Bicnu
MMelissa K Accordino
Phase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Thalomid
Bristol-Myers SquibbPhase 2
Camptosar
PfizerPhase 2
Avastin
BBio-Thera Solutions
Phase 2
Sutent
PfizerPhase 2
Leukine
SanofiPhase 2
Zofran
NovartisPhase 2
Imjudo
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TS-2021. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- BBeijing Neurosurgical Institute